Terms: = Sarcomas AND CDK6, MGC59692, 1021, Q00534, ENSG00000105810, PLSTIRE AND Treatment
37 results:
1. The Targeted Therapies for Osteosarcoma
Wang S; Ren Q; Li G; Zhao X; Zhao X; Zhang Z
Curr Mol Pharmacol; 2024; 17(1):e210823220109. PubMed ID: 37602543
[TBL] [Abstract] [Full Text] [Related]
2. Adjuvant Palbociclib May be Associated with Delayed Recurrence in Completely Resected Retroperitoneal Liposarcoma: Results of a Single-Institution Retrospective Cohort Study.
Selby LV; Clark EC; Liebner DA; Chen JL; Tinoco G; Bashian E; Beane JD; Pollock RE; Grignol VP
Ann Surg Oncol; 2023 Nov; 30(12):7876-7881. PubMed ID: 37330448
[TBL] [Abstract] [Full Text] [Related]
3. Oncogenic lncRNA ZNFX1 antisense RNA 1 promotes osteosarcoma cells proliferation and metastasis by stabilizing serine and arginine‑rich splicing factor 3.
Zhang Y; Xu W; Wang Y; Li J; He G; Guan M; Zeng X; Bian W; Song Y; Liu J
Bioengineered; 2022 Mar; 13(3):5962-5974. PubMed ID: 35184675
[TBL] [Abstract] [Full Text] [Related]
4. A murine mesenchymal stem cell model for initiating events in osteosarcomagenesis points to CDK4/cdk6 inhibition as a therapeutic target.
Franceschini N; Gaeta R; Krimpenfort P; Briaire-de Bruijn I; Kruisselbrink AB; Szuhai K; Palubeckaitė I; Cleton-Jansen AM; Bovée JVMG
Lab Invest; 2022 Apr; 102(4):391-400. PubMed ID: 34921235
[TBL] [Abstract] [Full Text] [Related]
5. microRNA-524-5p inhibits proliferation and induces cell cycle arrest of osteosarcoma cells via targeting cdk6.
Chen H; Cheng C; Gao S
Biochem Biophys Res Commun; 2020 Sep; 530(3):566-573. PubMed ID: 32747087
[TBL] [Abstract] [Full Text] [Related]
6. The Activity of Chemotherapy in Inflammatory Myofibroblastic Tumors: A Multicenter, European Retrospective Case Series Analysis.
Baldi GG; Brahmi M; Lo Vullo S; Cojocaru E; Mir O; Casanova M; Vincenzi B; De Pas TM; Grignani G; Pantaleo MA; Blay JY; Jones RL; Le Cesne A; Frezza AM; Gronchi A; Collini P; Dei Tos AP; Morosi C; Mariani L; Casali PG; Stacchiotti S
Oncologist; 2020 Nov; 25(11):e1777-e1784. PubMed ID: 32584482
[TBL] [Abstract] [Full Text] [Related]
7. circ_ARF3 regulates the pathogenesis of osteosarcoma by sponging miR-1299 to maintain cdk6 expression.
Gao AM; Yuan C; Hu AX; Liu XS
Cell Signal; 2020 Aug; 72():109622. PubMed ID: 32240746
[TBL] [Abstract] [Full Text] [Related]
8. Downregulated Long Non-Coding RNA MSC-AS1 Inhibits Osteosarcoma Progression and Increases Sensitivity to Cisplatin by Binding to MicroRNA-142.
Zhang L; Zhao G; Ji S; Yuan Q; Zhou H
Med Sci Monit; 2020 Mar; 26():e921594. PubMed ID: 32155139
[TBL] [Abstract] [Full Text] [Related]
9. Long intergenic non‑protein coding RNA 00460 predicts a poor prognosis and promotes tumorigenesis of human osteosarcoma.
Jiang JJ; Wang FC; Han LP
Mol Med Rep; 2020 Feb; 21(2):649-658. PubMed ID: 31974626
[TBL] [Abstract] [Full Text] [Related]
10. Sodium cantharidinate suppresses human osteosarcoma MG‑63 cell proliferation and induces cell cycle arrest by inhibition of PI3K/AKT activation.
Kong DL; Liu Y; Wang JY; Liu G; Zhang ML
Oncol Rep; 2019 Feb; 41(2):1351-1358. PubMed ID: 30535442
[TBL] [Abstract] [Full Text] [Related]
11. Advances of systemic treatment for adult soft-tissue sarcoma.
Liu W; Jiang Q; Zhou Y
Chin Clin Oncol; 2018 Aug; 7(4):42. PubMed ID: 30173532
[TBL] [Abstract] [Full Text] [Related]
12. CDK4 expression in chordoma: A potential therapeutic target.
Liu T; Shen JK; Choy E; Zhang Y; Mankin HJ; Hornicek FJ; Duan Z
J Orthop Res; 2018 Jun; 36(6):1581-1589. PubMed ID: 29194728
[TBL] [Abstract] [Full Text] [Related]
13. In vitro and in vivo anti-primary effusion lymphoma activities of fucoidan extracted from Cladosiphon okamuranus Tokida.
Ishikawa C; Mori N
Oncol Rep; 2017 Nov; 38(5):3197-3204. PubMed ID: 29048633
[TBL] [Abstract] [Full Text] [Related]
14. miR‑494 inhibits cell proliferation and metastasis via targeting of cdk6 in osteosarcoma.
Yuan W; Wang D; Liu Y; Tian D; Wang Y; Zhang R; Yin L; Deng Z
Mol Med Rep; 2017 Dec; 16(6):8627-8634. PubMed ID: 28990071
[TBL] [Abstract] [Full Text] [Related]
15. Distinct molecular subtypes of uterine leiomyosarcoma respond differently to chemotherapy treatment.
An Y; Wang S; Li S; Zhang L; Wang D; Wang H; Zhu S; Zhu W; Li Y; Chen W; Ji S; Guo X
BMC Cancer; 2017 Sep; 17(1):639. PubMed ID: 28893210
[TBL] [Abstract] [Full Text] [Related]
16. Current Status of Biological Therapies for the treatment of Metastatic Melanoma.
Tang T; Eldabaje R; Yang L
Anticancer Res; 2016 Jul; 36(7):3229-41. PubMed ID: 27354579
[TBL] [Abstract] [Full Text] [Related]
17. Genetically engineered pre-microRNA-34a prodrug suppresses orthotopic osteosarcoma xenograft tumor growth via the induction of apoptosis and cell cycle arrest.
Zhao Y; Tu MJ; Wang WP; Qiu JX; Yu AX; Yu AM
Sci Rep; 2016 May; 6():26611. PubMed ID: 27216562
[TBL] [Abstract] [Full Text] [Related]
18. Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With CDK4 Inhibitor Palbociclib: A Phase 2 Clinical Trial.
Dickson MA; Schwartz GK; Keohan ML; D'Angelo SP; Gounder MM; Chi P; Antonescu CR; Landa J; Qin LX; Crago AM; Singer S; Koff A; Tap WD
JAMA Oncol; 2016 Jul; 2(7):937-40. PubMed ID: 27124835
[TBL] [Abstract] [Full Text] [Related]
19. Protein inhibitor of activated STAT xα depresses cyclin D and cyclin D kinase, and contributes to the inhibition of osteosarcoma cell progression.
Wang J; Ni J; Yi S; Song D; Ding M
Mol Med Rep; 2016 Feb; 13(2):1645-52. PubMed ID: 26708148
[TBL] [Abstract] [Full Text] [Related]
20. Combination therapy with bioengineered miR-34a prodrug and doxorubicin synergistically suppresses osteosarcoma growth.
Zhao Y; Tu MJ; Yu YF; Wang WP; Chen QX; Qiu JX; Yu AX; Yu AM
Biochem Pharmacol; 2015 Dec; 98(4):602-13. PubMed ID: 26518752
[TBL] [Abstract] [Full Text] [Related]
[Next]
